The portfolio acquired includes Stugeron brand as well as its leading local brands STUGERON FORTE and STUGERON PLUS across 18 markets in the APAC and EMEA regions
Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Around 7% of the Indian population suffers from IBS
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Subscribe To Our Newsletter & Stay Updated
